SARstudies in a series of 3-heteroarylthio substituted cephalosporins established that high activity against methicillin-resistant Staphylococcus aureus (MRSA)can be achieved with various heteroaryl substituents. Early results showed that highly lipophilic 3-heteroarylthio substituents, which were necessary for anti-MRSA activity, caused high affinity of such cephems toward serum proteins. Our earlier published efforts described discovery of zwitterionic cephems 479) , where serum binding was reduced by employing basic, positively charged functionalities attached to the 3-heteroarylthio substituent. In order to avoid low solubility problems associated with most such zwitterionic cephalosporins a wide variety of non-basic heteroaryl substituents was tested (non-zwitterionic cephems are more easily formulated as water soluble sodium salts for intravenous administration). Considerable reduction in serum binding was obtained in some analogs while maintaining high anti-MRSA potency.
Methicillin-resistant Staphylococcus aureus (MRSA) is a commoncause of serious nosocomial infections]).
Restrictions in the use of vancomycin, a drug of choice against MRSAinfections, are presently recommended as a measure to decrease the emergence of vancomycinresistant Gram-positive organisms2 
and Microcide6) (3). (Fig. 1) .
The structural modifications introduced to these cephalosporins aim to increase the affinity of the drug molecule toward penicillin binding protein 2a (PBP 2a), which is the main mediator of resistance to methicillin.
Recently described kinetic studies of /J-lactam binding to PBP2a have provided important insight into the resistance mechanism at the molecular level7). In our early SAR studies of anti-MRSA cephalosporins, it became apparent that relatively high lipophilicity was required for high antiMRSApotency but was also one of the factors responsible for high serum binding of most potent compounds. The 3-(2-iodophenyl)thio cephalosporin derivative 48) exemplifies an anti-MRSA cephalosporin agent of high in vitro potency with extremely high serum protein binding, which precluded its antibacterial application in vivo. An avenue to reducing serum binding of such cephalosporins, by introducing positively charged functionalities, was successfully employed by us in the discovery of RWJ54428 (3). This approach resulted in a zwitterionic molecule, which requires low pH to achieve solubility necessary for parenteral administration. An alternative strategy seeks a non-zwitterionic analog which can be formulated as a highly soluble sodium salt at neutral pH. The present publication describes such an alternative strategy in which we tested the limits of reduction of the overall lipophilicity of the molecule without sacrificing anti-MRSA potency.
Preparation of key intermediates and general synthetic Acids I-III were coupled to the key benzhydryl protected 7-amino-3-methanesulfonyloxy-(V) or 7-amino-3-chloro-(VI) cephem intermediates to produce the corresponding amides VII a~d. In the ensuing reactions with thiols, depending on the character of the heterocyclic thiol, base induced isomerization leading to the undesired A2 cephem isomer (up to 80%) often could not be suppressed, and the desired A3 isomers of protected 3-heteroarylthiocephems had to be isolated by chromatography. The final 3-heteroarylthio cephalosporins 5-38 were obtained by deprotection with trifluoroacetie acid and, when necessary, were converted into the corresponding sodium salts.
In our early SAR studies of 3-arylthio and 3-heteroarylthio substituted cephalosporins8) we determined that the ortho substitution present in the aromatic substituent generally improved anti-MRSApotency relative to other attachment.positions. Therefore we have explored a class of 3-(or^/z6>-substituted-phenylthio)eephems (Table 1 ) with variations in phenyl ring and oxime substitution. High anti-MRSA activity was associated with either unsubstituted oxime (compound 7) or large lipophilic substituents attached to the oxime functionality (compounds 9, ll). However, analogs from this group were highly lipophilic, which adversely affected serum protein binding (e.g. human serum binding for the 2-cyanophenyl analog 12 is 99%). Potent anti-MRSA compounds were also found among a series of 3-(Af-phenylpyrazol-5-yl)-thiocephems ( Table 3 .
In an attempt to further reduce serum binding without the loss of anti-MRSA activity, a series of polyaza-6tt-thiocephalosporins was studied (Table 4) 
Materials and Methods

Susceptibility Testing
Compounds were evaluated for antimicrobial activity against a panel of bacterial strains using a broth microdilution assay performed as recommended by the NCCLS10). The minimum inhibitory concentration (MIC) is defined as the lowest concentration of a compound that prevents the growth of the bacteria.
Mouse Model of Sepsis
Inoculum Preparation: Staphylococcus aureus strain Smith (ATCC 13709, penicillin-susceptible) or strain 76 (methicillin-resistant) was grown overnight at 37°C in brain-heart infusion broth (BHIB). The following morning, it was subcultured to fresh BHIB and incubated for,4-5 hours at 37°C. The cells were harvested by centrifugation, washed twice with PBS, and adjusted to the desired inoculum. The cell suspension was mixed with an equal volume of sterile 14%hog-gastric mucinn). The inoculum was kept in an ice bath until used (<1 hour). were then observed for 72 hours. The total dose associated with 50% survival (ED50) was determined using the probit method12).
HumanSerum Binding
For selected compounds, the binding in pooled human serum was determined using ultrafirtration. Compounds were incubated in serum for 10 minutes at 37°C in a shaking water bath. Serum ultraflltrate was obtained by centrifugation of ultraflltration units (Amicon Gentrifree) for 20 minutes at 25°C. Drug content in ultraflltrate was quantified by HPLC using standards prepared in blank ultrafiltrate undergoing similar processing. For some compoundsestimated humanserum binding (HSB*) was calculated using the MICvalues against S. aureus ATCC29213 determined in growth medium (GM) and in a 1 : 1 mixture of growth mediumand humanserum (GM+HS).
HSB*=(MICGM+HS-MICGM)
/ MICGM 100% The synthetic methods utilized to prepare the compounds described herein are exemplified with the synthesis of compound 34. trityl ester (990mg, 1.05 mmol) in dichloromethane (21 ml) was added triethylsilane (ll ml) followed by addition of trifluoroacetic acid (21 ml). After 1 hour reaction at room temperature the reaction mixture was concentrated in vacuum and diisopropyl ether was added to the oily residue. The precipitated title product was filtered, thoroughly washed with additional diisopropyl ether and dried in vacuum (528mg, 95% 
